At a glance
ClinicalIndex Comparison RecordN/ACompleted· 78 enrolled
Drug / intervention
Misoprostol +1 moredrug
Likely dose
Misoprostol 400mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in Intrauterine Device Insertion for Nulliparous Women
In Brief
A clinical study evaluating Misoprostol and Placebo for Contraception. Completed, enrolled 78 participants across 1 site.
Detailed Summary
Because of misoprostol's known ability to cause cervical dilation, some family planning providers give their patients a dose of this drug prior to insertion. The goal of this study is to evaluate whether misoprostol prior to IUD insertion in nulliparous women eases insertion and decreases pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionSep 2011
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.0 years ago
Interventions
Misoprostoldrug
400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
Placebodrug
Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit